Total DNA methylation as a biomarker of DNA damage and tumor malignancy in intracranial meningiomas.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
    • Abstract:
      Background: Meningiomas are the most common primary intracranial tumors in adults. They are initially detected with neuroimaging techniques, but definite histological diagnosis requires tumor surgery to collect tumor tissue. Gross total resection is an optimal and final treatment for the majority of patients, followed by radiotherapy in malignant or refractory cases. However, there are a lot of uncertainties about i.a. the need for intervention in incidental cases, estimation of growth kinetics, risk of malignant transformation, or response to radiotherapy. Therefore a new diagnostic approach is needed. It has already been shown that epigenetics plays a crucial role in cancer biology, development, and progression. DNA methylation, the presence of 5-methylcytosine in DNA, is one of the main elements of a broad epigenetic program in a eukaryotic cell, with superior regulatory significance. Therefore, we decided to look at meningioma through changes of 5-methylcytosine.
      Methods: We performed an analysis of the total amount of 5-methylcytosine in DNA isolated from intracranial meningioma tissues and peripheral blood samples of the same patients. The separation and identification of radioactively labeled nucleotides were performed using thin-layer chromatography.
      Results: We found that the 5-methylcytosine level in DNA from intracranial meningiomas is inversely proportional to the malignancy grade. The higher the tumor WHO grade is, the lower the total DNA methylation. The amount of 5-methylcytosine in tumor tissue and peripheral blood is almost identical.
      Conclusions: We conclude that the total DNA methylation can be a useful marker for brain meningioma detection, differentiation, and monitoring. It correlates with tumor WHO grade, and the 5-methylcytosine level in peripheral blood reflects that in tumor tissue. Therefore it's applicable for liquid biopsy. Our study creates a scope for further research on epigenetic mechanisms in neurooncology and can lead to the development of new diagnostic methods in clinical practice.
    • References:
      Methods. 2015 Jan 15;72:3-8. (PMID: 25233806)
      Brain Pathol. 2010 May;20(3):623-31. (PMID: 19922547)
      Cell Res. 2011 Dec;21(12):1649-51. (PMID: 21862972)
      Mech Ageing Dev. 2012 Apr;133(4):157-68. (PMID: 22313689)
      Biomed Res Int. 2016;2016:2568635. (PMID: 27294112)
      Lancet Oncol. 2017 May;18(5):682-694. (PMID: 28314689)
      J Neurooncol. 2010 Sep;99(3):307-14. (PMID: 20821343)
      Cancer Epidemiol. 2019 Oct;62:101562. (PMID: 31325769)
      Cancer Invest. 2006 Feb;24(1):35-40. (PMID: 16466990)
      Acta Neuropathol. 2016 Jun;131(6):803-20. (PMID: 27157931)
      Neurosurg Focus. 2018 Apr;44(4):E3. (PMID: 29606052)
      Biosci Rep. 2018 Oct 22;38(5):. (PMID: 30254100)
      PLoS One. 2013;8(1):e54114. (PMID: 23349797)
      Genes Dis. 2018 Jan 31;5(1):1-8. (PMID: 30258928)
      DNA Repair (Amst). 2015 Aug;32:52-57. (PMID: 25956859)
      Clin Neurol Neurosurg. 2018 Jul;170:84-87. (PMID: 29753168)
      Neuro Oncol. 2010 Feb;12(2):173-80. (PMID: 20150384)
      Sci Rep. 2016 Aug 25;6:32067. (PMID: 27558167)
      Neuro Oncol. 2019 Mar 18;21(4):498-507. (PMID: 30615143)
      Nucleic Acids Res. 2014 Jun;42(11):7450-60. (PMID: 24852253)
      Int J Cancer. 2007 Oct 1;121(7):1473-80. (PMID: 17557299)
      Transl Res. 2012 Nov;160(5):355-62. (PMID: 22735029)
      Curr Opin Neurol. 2013 Dec;26(6):681-7. (PMID: 24184972)
      PLoS One. 2014 Mar 20;9(3):e92599. (PMID: 24651295)
      World Neurosurg. 2018 Nov;119:366-373. (PMID: 30138732)
      Science. 2013 Mar 1;339(6123):1077-80. (PMID: 23348505)
      Neuro Oncol. 2017 Oct 1;19(10):1298-1307. (PMID: 28419308)
      Clin Neurol Neurosurg. 2011 May;113(4):261-7. (PMID: 21227570)
      Nat Commun. 2017 Feb 14;8:14433. (PMID: 28195122)
      Lancet Neurol. 2006 Dec;5(12):1045-54. (PMID: 17110285)
      Carcinogenesis. 2012 Feb;33(2):436-41. (PMID: 22102699)
      Front Oncol. 2013 Sep 02;3:227. (PMID: 24032107)
      Mol Cancer Res. 2004 Mar;2(3):196-202. (PMID: 15037658)
      Nat Genet. 2013 Mar;45(3):285-9. (PMID: 23334667)
      Neurosurgery. 2009 Mar;64(3):455-61; discussion 461-2. (PMID: 19240607)
      Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80. (PMID: 16467088)
      J Cancer Res Clin Oncol. 2015 Sep;141(9):1593-601. (PMID: 25648363)
      Neuro Oncol. 2019 Jul 11;21(7):901-910. (PMID: 31158293)
      Nature. 1967 Oct 7;216(5110):84-5. (PMID: 6050684)
      Curr Drug Targets. 2015;16(1):13-9. (PMID: 25585126)
      Am J Cancer Res. 2017 May 01;7(5):1016-1036. (PMID: 28560055)
      Nat Med. 2011 Mar;17(3):330-9. (PMID: 21386836)
      Neuro Oncol. 2019 Dec 17;21(12):1498-1508. (PMID: 31276167)
      BMC Cancer. 2014 Nov 17;14:830. (PMID: 25403427)
      PLoS Genet. 2018 Jun 7;14(6):e1007362. (PMID: 29879107)
      Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. (PMID: 31675094)
      J Appl Genet. 2013 Aug;54(3):335-44. (PMID: 23661397)
      J Neurosurg. 2001 Oct;95(4):601-7. (PMID: 11596954)
      Cells. 2019 Sep 11;8(9):. (PMID: 31514401)
      Life Sci. 2016 Mar 1;148:183-93. (PMID: 26851532)
      Cell Death Dis. 2016 Jun 09;7(6):e2253. (PMID: 27277675)
      Mutat Res. 2011 Jun 3;711(1-2):193-201. (PMID: 21216256)
      J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):378-387. (PMID: 32041819)
      J Neurooncol. 2011 Jul;103(3):533-9. (PMID: 20862517)
      Expert Rev Neurother. 2018 Mar;18(3):241-249. (PMID: 29338455)
      Epigenetics Chromatin. 2015 Jul 21;8:24. (PMID: 26195987)
      Front Cell Dev Biol. 2014 Sep 09;2:49. (PMID: 25364756)
      Annu Rev Biochem. 2014;83:585-614. (PMID: 24905787)
    • Contributed Indexing:
      Keywords: 5-methylcytosine; Biomarker; DNA damage; DNA methylation; Meningioma
    • Accession Number:
      0 (Biomarkers, Tumor)
      6R795CQT4H (5-Methylcytosine)
      9007-49-2 (DNA)
    • Publication Date:
      Date Created: 20200605 Date Completed: 20210111 Latest Revision: 20210111
    • Publication Date:
      20240104
    • Accession Number:
      PMC7268775
    • Accession Number:
      10.1186/s12885-020-06982-3
    • Accession Number:
      32493231